Vaccines, Vol. 6, Pages 12: Meningococcal Vaccines: Current Status and Emerging Strategies

Vaccines, Vol. 6, Pages 12: Meningococcal Vaccines: Current Status and Emerging Strategies

Vaccines doi: 10.3390/vaccines6010012

Authors: Pumtiwitt C. McCarthy Abeer Sharyan Laleh Sheikhi Moghaddam

Neisseria meningitidis causes most cases of bacterial meningitis. Meningococcal meningitis is a public health burden to both developed and developing countries throughout the world. There are a number of vaccines (polysaccharide-based, glycoconjugate, protein-based and combined conjugate vaccines) that are approved to target five of the six disease-causing serogroups of the pathogen. Immunization strategies have been effective at helping to decrease the global incidence of meningococcal meningitis. Researchers continue to enhance these efforts through discovery of new antigen targets that may lead to a broadly protective vaccine and development of new methods of homogenous vaccine production. This review describes current meningococcal vaccines and discusses some recent research discoveries that may transform vaccine development against N. meningitidis in the future.

from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2sOslkI
via IFTTT